Chemistry:Enlicitide chloride
From HandWiki
Short description: Chemical compound
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C82H110ClFN14O15 |
| Molar mass | 1586.31 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Enlicitide chloride (INN;[1] previously known as MK-0616) is a macrocyclic peptide investigational drug that is being evaluated for the treatment of hypercholesterolaemia. It is a PCSK9 inhibitor.[2]
Merck has launched a Phase 3 clinical trial to evaluate the efficacy and safety of MK-0616 in Adults With Hypercholesterolemia. [3][4]
References
- ↑ "Recommended International Nonproprietary Names: List 90". WHO Drug Information 37 (3): 753–754. ISBN 978-92-4-008139-0. https://iris.who.int/bitstream/handle/10665/373341/9789240081390-eng.pdf.
- ↑ "MK-0616: an oral PCSK9 inhibitor for hypercholesterolemia treatment". Expert Opinion on Investigational Drugs 32 (10): 873–878. 2023. doi:10.1080/13543784.2023.2267972. PMID 37815341.
- ↑ "A Study of MK-0616 (Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids". 2024-05-17. https://clinicaltrials.gov/study/NCT05952856?id=NCT05952856&rank=1.
- ↑ "The MK-0616 Information Center". 2024-07-07. https://mk-0616.com.
